0000000000627837

AUTHOR

Lorenzo Bertani

showing 5 related works from this author

Telemedicine and Remote Screening for COVID-19 in Inflammatory Bowel Disease Patients: Results From the SoCOVID-19 Survey

2020

Telemedicinemedicine.medical_specialtytelemedicine; COVID-19; inflammatory bowel disease; Aftercare; Betacoronavirus; Hospitalization; Humans; Infection Control; Italy; Mass Screening; Organizational Innovation; Remote Consultation; Surveys and Questionnaires; Coronavirus Infections; Hospital Units; Inflammatory Bowel Diseases; Pandemics; Pneumonia Viral; TelemedicinePneumonia ViralAftercareInflammatory bowel diseaselaw.inventionSettore MED/12Betacoronaviruslawinflammatory bowel diseaseSurveys and QuestionnairesmedicineInfection controlImmunology and AllergyHumansMass ScreeningViralLetters to the EditorPandemicsMass screeningAcademicSubjects/MED00260Remote ConsultationCOVID-19; inflammatory bowel disease; telemedicine; Aftercare; Betacoronavirus; COVID-19; Hospitalization; Humans; Infection Control; Italy; Mass Screening; Organizational Innovation; Remote Consultation; SARS-CoV-2; Surveys and Questionnaires; Coronavirus Infections; Hospital Units; Inflammatory Bowel Diseases; Pandemics; Pneumonia Viral; TelemedicineInfection Controlbusiness.industrySARS-CoV-2Remote ConsultationGastroenterologyCOVID-19PneumoniaBiological productmedicine.diseaseInflammatory Bowel DiseasesIntensive care unitOrganizational InnovationTelemedicineHospitalizationDiarrheaItalyEmergency medicinemedicine.symptomtelemedicine; COVID-19; inflammatory bowel diseasebusinessCoronavirus InfectionsHospital UnitsInflammatory Bowel Diseases
researchProduct

sj-pdf-1-ueg-10.1177_2050640620964132 - Supplemental material for Activities related to inflammatory bowel disease management during and after the co…

2020

Supplemental material, sj-pdf-1-ueg-10.1177_2050640620964132 for Activities related to inflammatory bowel disease management during and after the coronavirus disease 2019 lockdown in Italy: How to maintain standards of care by Simone Saibeni, Ludovica Scucchi, Gabriele Dragoni, Cristina Bezzio, Agnese Miranda, Davide Giuseppe Ribaldone, Angela Bertani, Fabrizio Bossa, Mariangela Allocca, Andrea Buda, Gianmarco Mocci, Alessandra Soriano, Silvia Mazzuoli, Lorenzo Bertani, Flavia Baccini, Erika Loddo, Antonino Carlo Privitera, Alessandro Sartini, Angelo Viscido, Laurino Grossi, Valentina Casini, Viviana Gerardi, Marta Ascolani, Mirko Di Ruscio, Giovanni Casella, Edoardo Savarino, Davide Strade…

FOS: Clinical medicineFOS: Biological sciences111199 Nutrition and Dietetics not elsewhere classifiedFOS: Health sciences110308 Geriatrics and Gerontology69999 Biological Sciences not elsewhere classified111299 Oncology and Carcinogenesis not elsewhere classified
researchProduct

Activities related to inflammatory bowel disease management during and after the coronavirus disease 2019 lockdown in Italy: How to maintain standard…

2020

BACKGROUND AND AIMS: Restructuring activities have been necessary during the lockdown phase of the coronavirus disease 2019 (COVID-19) pandemic. Few data are available on the post-lockdown phase in terms of health-care procedures in inflammatory bowel disease (IBD) care, and no data are available specifically from IBD units. We aimed to investigate how IBD management was restructured during the lockdown phase, the impact of the restructuring on standards of care and how Italian IBD units have managed post-lockdown activities. METHODS: A web-based online survey was conducted in two phases (April and June 2020) among the Italian Group for IBD affiliated units within the entire country. We inv…

Crohn’s diseasemedicine.medical_specialtystandards of careCOVID-19; Crohn’s disease; Inflammatory bowel disease; standards of care; therapy; ulcerative colitis; COVID-19; Critical Pathways; Disease Management; Humans; Inflammatory Bowel Diseases; Italy; Pandemics; Public Health Surveillance; Quality of Life; Surveys and Questionnaires; Standard of CareInflammatory bowel diseaseInflammatory bowel disease03 medical and health sciences0302 clinical medicineQuality of life (healthcare)Public health surveillanceAmbulatory careSurveys and QuestionnairesPandemicmedicineHumansPublic Health SurveillanceDisease management (health)Intensive care medicinePandemicsulcerative colitisCrohn's diseasetherapybusiness.industryGastroenterologyDisease ManagementCOVID-19Standard of Caremedicine.diseaseInflammatory Bowel DiseasesUlcerative colitisOncologyItalyCOVID-19; Crohn’s disease; Inflammatory bowel disease; standards of care; therapy; ulcerative colitis030220 oncology & carcinogenesisCritical PathwaysQuality of Life030211 gastroenterology & hepatologybusiness
researchProduct

sj-pdf-1-ueg-10.1177_2050640620964132 - Supplemental material for Activities related to inflammatory bowel disease management during and after the co…

2020

Supplemental material, sj-pdf-1-ueg-10.1177_2050640620964132 for Activities related to inflammatory bowel disease management during and after the coronavirus disease 2019 lockdown in Italy: How to maintain standards of care by Simone Saibeni, Ludovica Scucchi, Gabriele Dragoni, Cristina Bezzio, Agnese Miranda, Davide Giuseppe Ribaldone, Angela Bertani, Fabrizio Bossa, Mariangela Allocca, Andrea Buda, Gianmarco Mocci, Alessandra Soriano, Silvia Mazzuoli, Lorenzo Bertani, Flavia Baccini, Erika Loddo, Antonino Carlo Privitera, Alessandro Sartini, Angelo Viscido, Laurino Grossi, Valentina Casini, Viviana Gerardi, Marta Ascolani, Mirko Di Ruscio, Giovanni Casella, Edoardo Savarino, Davide Strade…

FOS: Clinical medicineFOS: Biological sciences111199 Nutrition and Dietetics not elsewhere classifiedFOS: Health sciences110308 Geriatrics and Gerontology69999 Biological Sciences not elsewhere classified111299 Oncology and Carcinogenesis not elsewhere classified
researchProduct

The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy.

2019

BACKGROUND We report a prospective, nationwide cohort evaluating the safety and effectiveness of CT-P13. METHODS A structured database was used to record serious adverse events (SAEs), clinical remission/response, inflammatory biomarkers (CRP and calprotectin), and endoscopic findings. RESULTS Eight hundred ten patients with inflammatory bowel disease (IBD) (452 Crohn's disease [CD]) were enrolled. Four hundred fifty-nine patients were naive to anti-TNFα (group A), 196 had a previous exposure (group B), and the remaining 155 were switched to CT-P13 (group C). All patients were included in the safety evaluation with a mean follow-up of 345 ± 215 days and a total number of 6501 infusions. One…

0301 basic medicineAdultMalemedicine.medical_specialtyAdolescentSettore MED/12 - GASTROENTEROLOGIABiosimilar; Crohn's disease; CT-P13; Inflammatory bowel disease; Inflectra; Infliximab; Remsima; Ulcerative colitis; Adolescent; Adult; Antibodies Monoclonal; Female; Follow-Up Studies; Gastrointestinal Agents; Humans; Inflammatory Bowel Diseases; Infliximab; Italy; Male; Prognosis; Prospective Studies; Young AdultInflectraInflammatory bowel diseaseInflammatory bowel diseaseAntibodies03 medical and health sciencesYoung Adult0302 clinical medicineGastrointestinal AgentsInternal medicineMonoclonalmedicineImmunology and AllergyHumansProspective StudiesRemsimaProspective cohort studyCrohn's diseasebusiness.industryCrohn's disease; ulcerative colitis; inflammatory bowel disease; Infliximab; Remsima; Inflectra; biosimilar; CT-P13BiosimilarSettore MED/09 - MEDICINA INTERNAGastroenterologyAntibodies Monoclonalmedicine.diseaseInflammatory Bowel DiseasesPrognosisUlcerative colitisInfliximabInfliximabCrohn's disease030104 developmental biologyUlcerative colitisItalyCohort030211 gastroenterology & hepatologyFemaleCalprotectinbusinessCT-P13Cohort studymedicine.drugFollow-Up StudiesInflammatory bowel diseases
researchProduct